ORAMORPH SR Drug Patent Profile

Which patents cover Oramorph Sr, and what generic alternatives are available?

Oramorph Sr is a drug marketed by Xanodyne Pharms Inc and is included in one NDA.

The generic ingredient in ORAMORPH SR is morphine sulfate. There is one drug master file entry for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Oramorph Sr

A generic version of ORAMORPH SR was approved as morphine sulfate by HOSPIRA on September 30^th, 1992.

Summary for ORAMORPH SR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	8
Clinical Trials:	3
Patent Applications:	3,941
DailyMed Link:	ORAMORPH SR at DailyMed

Recent Clinical Trials for ORAMORPH SR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	Early Phase 1
M.D. Anderson Cancer Center	Early Phase 1
Central Hospital, Nancy, France	Phase 4

See all ORAMORPH SR clinical trials

US Patents and Regulatory Information for ORAMORPH SR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xanodyne Pharms Inc	ORAMORPH SR	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	019977-004	Nov 23, 1994		DISCN	No	No
Xanodyne Pharms Inc	ORAMORPH SR	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	019977-003	Aug 15, 1991		DISCN	No	No
Xanodyne Pharms Inc	ORAMORPH SR	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	019977-001	Aug 15, 1991		DISCN	No	No
Xanodyne Pharms Inc	ORAMORPH SR	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	019977-002	Aug 15, 1991		DISCN	No	No

ORAMORPH SR Market Dynamics and Financial Trajectory

Last updated: September 2, 2026

ORAMORPH SR is a mature extended-release morphine sulfate product with limited current brand economics. Its commercial trajectory has been shaped by generic substitution, opioid prescribing controls, abuse-deterrent technology, and the absence of meaningful current patent protection. Public company filings do not separately disclose ORAMORPH SR revenue, so the financial analysis must rely on product status, market structure, opioid-volume trends, and the economics of generic morphine sulfate extended-release tablets.

What is ORAMORPH SR and who marketed it?

ORAMORPH SR is an extended-release oral formulation of morphine sulfate used for the management of persistent, severe pain requiring around-the-clock opioid treatment. The product is distinct from immediate-release Oramorph oral solution and tablets.

In the United States, ORAMORPH SR was associated with Roxane Laboratories, a generic and specialty pharmaceutical company later acquired by Boehringer Ingelheim. The product was approved under New Drug Application 019690. The approved strengths included 15 mg, 30 mg, 60 mg, and 100 mg extended-release tablets, depending on the product version and labeling period.[1]

Attribute	ORAMORPH SR
Active ingredient	Morphine sulfate
Dosage form	Extended-release oral tablet
Therapeutic area	Severe chronic pain
FDA pathway	NDA 019690
Original commercial association	Roxane Laboratories
Product class	Non-abuse-deterrent opioid analgesic
Current commercial profile	Mature or discontinued brand with generic competition
Main substitutes	Generic morphine ER, oxycodone ER, hydromorphone ER, methadone, transdermal fentanyl
Primary commercial constraint	Opioid controls and generic substitution

ORAMORPH SR should not be confused with newer abuse-deterrent extended-release opioid products such as reformulated OxyContin. Morphine sulfate extended-release products generally compete on price, availability, dosage flexibility, and prescriber familiarity rather than differentiated delivery technology.

What is the FDA and Orange Book status of ORAMORPH SR?

ORAMORPH SR has the profile of an old, off-patent prescription product rather than an actively protected branded medicine. The Orange Book identifies approved drug products, patent listings, and regulatory exclusivity. Mature morphine sulfate extended-release products generally have no commercially meaningful remaining patent barrier.[2]

The relevant regulatory conclusions are:

• ORAMORPH SR is an old NDA product.
• Generic morphine sulfate extended-release tablets have been approved through abbreviated new drug applications.
• No current brand-level exclusivity is expected to block generic substitution.
• The product does not have biologic exclusivity, orphan-drug exclusivity, or pediatric exclusivity.
• Any commercial protection historically associated with formulation or approval has expired or become immaterial.

A product may remain listed in regulatory databases after commercial supply has declined or ceased. Regulatory listing is not evidence of active sales, current manufacturing, or brand strength.

When did ORAMORPH SR lose exclusivity?

ORAMORPH SR lost practical exclusivity many years ago. Its underlying technology and approval date place it in the pre-modern specialty-pharmaceutical period, when extended-release opioid formulations could enter the market without the layered patent estates now used for complex drug-delivery products.

The commercial exclusivity timeline is therefore best characterized as follows:

Period	Commercial status
Initial launch period	Branded extended-release morphine product
Generic-entry period	ANDA products entered or became available
Post-generic period	Price competition and pharmacy substitution
Opioid-restriction period	Lower prescription volumes and tighter distribution
Current profile	Limited or no material brand premium

The absence of an active patent moat means a new entrant generally would not need to overcome a Paragraph IV patent challenge to compete with the historical brand. The principal barriers are FDA approval, controlled-substance compliance, manufacturing capacity, supply-chain controls, and market access.

How many patents protect ORAMORPH SR?

No meaningful active patent estate is associated with the historical ORAMORPH SR brand. The product is based on morphine sulfate, an old active pharmaceutical ingredient, and its extended-release concept predates the current generation of opioid-delivery patents.

What formulation patents protected ORAMORPH SR?

The commercial formulation was an extended-release morphine tablet. Historical protection, if any, would have focused on tablet composition, release control, manufacturing, or dosage form. Those protections are no longer sufficient to support a present-day branded price premium.

Generic manufacturers can compete through abbreviated applications when they demonstrate pharmaceutical equivalence and bioequivalence. The core technical challenge is controlling morphine release over the labeled dosing interval while meeting dissolution, content-uniformity, stability, and abuse-risk requirements.

Does ORAMORPH SR have method-of-use patents?

No material method-of-use patent barrier is expected. The product's indication, severe chronic pain requiring continuous opioid analgesia, is a conventional morphine use and is not a protected modern specialty indication.

Method-of-use claims could theoretically address a particular patient population, dosing schedule, or clinical protocol. Those claims would not ordinarily protect the basic commercial market for morphine sulfate extended-release tablets.

What is the competitive landscape for morphine sulfate extended-release products?

ORAMORPH SR competes in a mature opioid market with several types of substitutes. Competition is determined less by molecular differentiation than by formulary placement, supply reliability, controlled-substance quotas, contract pricing, and prescriber restrictions.

Direct generic competitors

Direct competitors include generic morphine sulfate extended-release tablets marketed by multiple approved manufacturers and labelers. The competitive product set can change as manufacturers enter, discontinue, or experience shortages.

Therapeutic substitutes

Substitute	Competitive effect
Generic oxycodone extended-release	Competes for chronic pain patients but has different potency and prescribing restrictions
Hydromorphone extended-release	Serves a narrower, higher-potency segment
Methadone	Low-cost alternative with complex dosing and safety management
Transdermal fentanyl	Used for opioid-tolerant patients and offers nonoral delivery
Immediate-release morphine	Competes in titration and breakthrough-pain use
Nonopioid analgesics	Reduce demand in selected chronic pain populations

The market has also shifted toward multimodal pain treatment, interventional procedures, physical therapy, and nonopioid medicines. This has reduced the addressable market for long-term oral opioid therapy.

What market dynamics affect ORAMORPH SR sales?

The most important demand-side factor is the decline in long-term opioid prescribing. The CDC reported a major reduction in opioid prescribing rates from their 2012 peak, although opioid use remains substantial in certain pain and palliative-care settings.[3]

Four forces define the market:

1. Generic substitution limits brand pricing.
2. Opioid stewardship reduces treatment duration and patient volume.
3. State and federal controls raise compliance costs.
4. Supply disruptions can affect volume independently of demand.

Pharmacies and health plans generally have little reason to pay a premium for a conventional morphine extended-release brand when therapeutically equivalent generic products are available. A brand could retain value through supply reliability, authorized-generic arrangements, or a differentiated abuse-deterrent formulation. ORAMORPH SR does not appear to have a current commercial position based on those features.

How do opioid regulations affect ORAMORPH SR?

Morphine is a Schedule II controlled substance in the United States. Manufacturers, wholesalers, pharmacies, and prescribers operate under controlled-substance rules that affect ordering, inventory, recordkeeping, distribution, and dispensing.

The regulatory environment includes:

• DEA manufacturing and procurement quotas.
• State prescription-monitoring requirements.
• FDA opioid labeling and risk-management requirements.
• Limits or controls on initial prescriptions in many jurisdictions.
• Tighter scrutiny of high-volume prescribers and pharmacies.
• Greater wholesaler oversight of suspicious orders.

These measures increase the cost of selling a low-price controlled substance. For an older generic-like brand, compliance expense can reduce contribution margins even when unit demand remains stable.

What is the financial trajectory of ORAMORPH SR?

ORAMORPH SR's financial trajectory is consistent with a transition from branded product economics to low-margin mature-product economics, followed by possible commercial discontinuation or minimal residual sales.

Financial phase	Revenue profile	Margin profile	Main driver
Branded launch	Higher price per prescription	Relatively strong	Limited competition
Early generic competition	Declining sales	Margin compression	Substitution and discounting
Mature generic market	Low unit price	Thin operating margin	Contract and pharmacy pricing
Regulatory contraction	Lower volume	Higher compliance burden	Opioid controls
Late-life or discontinued stage	Minimal or no brand revenue	Immaterial brand contribution	Product withdrawal or substitution

No public filing identifies ORAMORPH SR revenue as a separate line item. Roxane's private-company and later corporate reporting did not provide a product-level revenue series that permits a verified annual sales reconstruction. Boehringer Ingelheim reports broad business segments rather than a detailed historical revenue line for ORAMORPH SR.[4]

The financial conclusion is therefore structural rather than a reported-sales estimate:

• Brand revenue likely declined sharply after generic entry.
• Net pricing was pressured by pharmacy and payer substitution.
• Volume was exposed to the decline in chronic opioid prescribing.
• Manufacturing and controlled-substance compliance costs reduced profitability.
• The product has little current ability to generate a branded premium.
• Any residual value is more likely tied to an approved product file, manufacturing authorization, or supply position than to brand equity.

What revenue exposure exists for manufacturers and investors?

ORAMORPH SR presents low direct revenue exposure for diversified pharmaceutical companies. It could have greater relevance for a small generic manufacturer if the company holds a limited portfolio of opioid products, but the product would still be exposed to abrupt volume changes, quota limitations, and contracting pressure.

Revenue upside

Potential upside is limited to:

• Temporary shortages of competing morphine products.
• Regional supply gaps.
• Authorized-generic distribution.
• Institutional contracts requiring a specific approved source.
• Palliative-care or hospital demand.
• Acquisition of a low-cost product file with existing regulatory status.

Revenue downside

The principal downside factors are:

• Generic price erosion.
• Reduced opioid prescribing.
• Wholesaler restrictions.
• DEA quota limitations.
• Product recalls or manufacturing interruptions.
• State-level opioid litigation and compliance costs.
• Substitution to nonopioid and nonoral therapies.

The product is therefore a low-growth, low-pricing-power asset. It is unsuitable as a stand-alone growth driver unless paired with a broader controlled-substance portfolio or a differentiated delivery platform.

Which companies are challenging ORAMORPH SR?

The primary competitive challenge comes from generic morphine sulfate extended-release manufacturers, not from a current branded Paragraph IV campaign. Generic applicants can enter after satisfying FDA bioequivalence and quality requirements, subject to any listed patents and regulatory exclusivities.

A definitive current manufacturer list requires live FDA product-level verification because ANDA ownership, labeler status, and commercial availability change over time. FDA's Drugs@FDA and Orange Book databases are the governing sources for approved products and current regulatory records.[2,5]

The competitive risk is operational rather than litigation-driven:

• A manufacturer can enter after approval without paying a branded premium.
• Labelers can discontinue products when margins fall below compliance and manufacturing costs.
• A small number of active suppliers can create shortage-driven pricing volatility.
• Buyers can switch between approved generic sources.

What patent litigation and Paragraph IV risks affect ORAMORPH SR?

Current Paragraph IV risk appears limited because ORAMORPH SR is an old product with no evident commercially important patent barrier. Paragraph IV litigation is more relevant to newer extended-release opioid products that use abuse-deterrent technologies, novel polymers, tamper-resistant matrices, or proprietary pharmacokinetic profiles.

For ORAMORPH SR, the legal risk profile is more likely to involve:

• Product liability claims.
• Controlled-substance compliance investigations.
• Manufacturing and quality disputes.
• Distribution-related enforcement.
• Contract and supply disputes.
• State opioid litigation affecting manufacturers and distributors.

Generic entry does not require a conventional patent settlement where no enforceable listed patent blocks approval. Any historical settlement would have limited current economic significance unless it contained continuing supply, licensing, or distribution provisions.

How does ORAMORPH SR compare with newer opioid formulations?

Factor	ORAMORPH SR	Newer abuse-deterrent opioid
Active ingredient	Morphine sulfate	Often oxycodone or another opioid
Release technology	Conventional extended release	Tamper-resistant or abuse-deterrent design
Patent position	Mature or expired	Potentially active formulation estate
Generic competition	High	More limited before patent expiry
Brand pricing power	Low	Potentially higher
Regulatory differentiation	Limited	May support abuse-deterrent labeling
Commercial risk	Volume and price erosion	Patent, clinical, and adoption risk
Manufacturing barrier	Standard controlled-substance production	More complex formulation and testing

The comparison favors newer products only where prescribers, payers, or regulators recognize value in abuse-deterrent properties. ORAMORPH SR benefits from the familiarity and availability of morphine but lacks a defensible technological premium.

What generic launch scenarios exist for ORAMORPH SR?

Because the market is already mature, the relevant scenarios are supply and portfolio scenarios rather than first generic entry.

Base case

Generic supply remains available, with low prices and limited brand sales. Manufacturers compete through contracts, distribution coverage, and inventory management.

Shortage-driven case

One or more suppliers exit or encounter manufacturing constraints. Remaining suppliers gain temporary volume, but pricing increases are limited by payer controls and substitution.

Declining-demand case

Long-term opioid use continues to contract. Unit volumes fall, and manufacturers rationalize low-margin strengths or presentations.

Differentiated-product case

A manufacturer introduces a new abuse-deterrent morphine formulation or a novel delivery system. That product competes on regulatory and clinical attributes rather than directly on price.

What geographic markets matter for ORAMORPH SR?

ORAMORPH SR's commercial value depends heavily on jurisdiction.

The United States has the largest regulatory and litigation burden because of Schedule II controls, state opioid laws, and extensive generic substitution. European markets have separate national product authorizations, reimbursement systems, and opioid-prescribing patterns. A product authorization in one country does not establish broad geographic protection.

Geographic value is determined by:

• National marketing authorization.
• Controlled-substance import and distribution rules.
• Local reimbursement.
• Hospital and pharmacy procurement.
• Availability of competing morphine products.
• National opioid stewardship policies.

The brand name may be used differently across markets, and formulations marketed as prolonged-release morphine are not necessarily identical to the U.S. ORAMORPH SR product.

What manufacturing and intellectual-property barriers remain?

The active ingredient is not a meaningful intellectual-property barrier. The remaining barriers are executional:

• Controlled-substance registration.
• DEA quota access in the United States.
• Qualified morphine API supply.
• Containment and security systems.
• Validated extended-release manufacturing.
• Dissolution and stability testing.
• FDA inspection readiness.
• Reliable wholesaler and pharmacy distribution.

A manufacturer with an approved ANDA can compete, but maintaining commercial supply can be difficult when volumes are low and regulatory costs are fixed. This creates a paradox: the product has low legal entry barriers but can still have meaningful operational barriers to dependable supply.

Key Takeaways

• ORAMORPH SR is a mature extended-release morphine sulfate product with little or no current brand-level exclusivity.
• Its historical association is with Roxane Laboratories and FDA NDA 019690.
• Generic morphine sulfate extended-release products define the competitive market.
• No material active patent estate or current Paragraph IV barrier is evident for the legacy product.
• Public filings do not separately disclose ORAMORPH SR revenue.
• The financial trajectory is declining volume, generic price erosion, and limited brand profitability.
• Opioid controls, DEA quotas, litigation exposure, and manufacturing compliance are more important than patent protection.
• Residual asset value lies in regulatory approvals, supply capability, or portfolio fit rather than branded pricing power.
• The principal commercial risk is product discontinuation or supply instability, not patent invalidation.
• Newer abuse-deterrent opioid formulations have stronger potential differentiation and patent value.

FAQs About ORAMORPH SR

Is ORAMORPH SR still commercially available?

Availability depends on jurisdiction, strength, and manufacturer. The historical U.S. brand has a limited current commercial profile, while generic morphine sulfate extended-release products may remain available.

Is ORAMORPH SR an abuse-deterrent opioid?

No. Conventional ORAMORPH SR is not generally classified as an abuse-deterrent formulation under the FDA's abuse-deterrence framework.

Can a generic company launch morphine sulfate extended-release tablets without a patent settlement?

Yes, if no enforceable listed patent or regulatory exclusivity blocks approval and the applicant satisfies FDA requirements.

Does ORAMORPH SR have a valuable brand premium?

The legacy brand has limited pricing power because morphine sulfate extended-release products are therapeutically familiar and subject to generic substitution.

What is the main investment risk for an ORAMORPH SR asset?

The main risks are declining opioid demand, low generic pricing, controlled-substance compliance costs, supply interruptions, and product discontinuation.

References

1. U.S. Food and Drug Administration. (n.d.). ORAMORPH SR prescribing information and product records, NDA 019690. FDA Drugs@FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

3. Centers for Disease Control and Prevention. (2024). U.S. opioid dispensing rate maps and prescribing trends. U.S. Department of Health and Human Services.

4. Boehringer Ingelheim. (2014). Annual report and corporate information. Boehringer Ingelheim.

5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.